Transgene . (NASDAQ:TRGNY)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Transgene . Charts. Click Here for more Transgene . Charts.](/p.php?pid=staticchart&s=N%5ETRGNY&p=8&t=15)
Transgene Appoints Philippe Archinard As New Chief Executive
Officer
STRASBOURG, France, Dec. 8 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY;
Euronext: FR0005175080) announced today that its Board of Directors chaired by
Dr. Christophe Merieux yesterday appointed Philippe Archinard as the new Chief
Executive Officer ("CEO") and Board Director. He replaces Jean-Francois
Carmier, who is leaving Transgene for personal reasons. The Board of Directors
expressed its thanks to Jean-Francois Carmier for his contribution to the
development of Transgene (the "Company").
"We are very happy to welcome Philippe Archinard to Transgene," stated Dr.
Christophe Merieux, Chairman of Transgene. "Philippe's background as former CEO
of the biotechnology company Innogenetics and his international experience will
accelerate our Company's developments."
Philippe Archinard, 45, began his career with bioMerieux where he held various
positions for 15 years in France and the United States, including CEO of the
U.S. operations. Since March 2000, he has served as Chief Executive Officer of
Innogenetics. He holds a chemical engineering degree and a PhD in biochemistry
from Lyon University, and has completed the PMD program at the Harvard Business
School.
In addition, the Board of Directors was informed by the principal shareholder
of Transgene of its commitment to cover Transgene's cash needs until the end of
2005 unless another financing option is adopted during this timeframe, in order
for the new CEO to develop and implement his strategy.
About Transgene
Transgene, based in Strasbourg, France, is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines,
immunotherapy products, and delivery technologies for the treatment of diseases
for which there is no cure or adequate treatment at present, with a focus on
the treatment of cancer. Transgene has five products in clinical development,
two of which are in Phase II clinical trials, two in Phase I/II clinical trials
and one that has completed a Phase I clinical trial. Transgene's proprietary
vector technology platform consists of adenoviral and poxviral families.
This press release contains forward-looking information regarding the funding
of Transgene's operations through the end of 2005. This information reflects
statements made by the Company's principal shareholder at the Board of
Directors meeting on December 7, 2004. It is not a guaranty by the Company of
on-going operations or future performance.
DATASOURCE: Transgene
CONTACT: Transgene, +33-3-88-27-91-01; Michael Long, Cohn & Wolfe,
+1-415-365-8523, for Transgene; Tiphaine Hecketsweiler, Image 7,
+33-1-53-70-74-59, for Transgene